Immunovant Inc (NASDAQ: IMVT)’s stock price has plunge by 1.25relation to previous closing price of 16.74. Nevertheless, the company has seen a 10.50% surge in its stock price over the last five trading sessions. zacks.com reported 2025-06-02 that Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?
Additionally, the 36-month beta value for IMVT is 0.62. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMVT is 68.57M and currently, short sellers hold a 31.62% ratio of that float. The average trading volume of IMVT on June 11, 2025 was 1.75M shares.
IMVT’s Market Performance
IMVT’s stock has seen a 10.50% increase for the week, with a 16.49% rise in the past month and a -11.35% fall in the past quarter. The volatility ratio for the week is 3.49%, and the volatility levels for the past 30 days are at 2.81% for Immunovant Inc The simple moving average for the past 20 days is 12.11% for IMVT’s stock, with a -26.35% simple moving average for the past 200 days.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Jefferies repeating the rating for IMVT by listing it as a “Hold.” The predicted price for IMVT in the upcoming period, according to Jefferies is $20 based on the research report published on March 03, 2025 of the current year 2025.
Raymond James gave a rating of “Outperform” to IMVT, setting the target price at $36 in the report published on October 10th of the previous year.
IMVT Trading at 13.21% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.83% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from WILLIAM MACIAS, who proposed sale 80,000 shares at the price of $15.61 back on Jun 03 ’25. After this action, WILLIAM MACIAS now owns shares of Immunovant Inc, valued at $1,248,616 using the latest closing price.
GEORGE V MIGAUSKY, the Former Director of Immunovant Inc, proposed sale 21,812 shares at $14.58 during a trade that took place back on May 21 ’25, which means that GEORGE V MIGAUSKY is holding shares at $318,047 based on the most recent closing price.
Stock Fundamentals for IMVT
The net margin for Immunovant Inc stands at -2586.5. Equity return is now at value -62.46, with -57.32 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -3835.45.
When we switch over and look at the enterprise to sales, we see a ratio of 13575.37. The receivables turnover for the company is 0.08for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.16.
Conclusion
In conclusion, Immunovant Inc (IMVT) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
